PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $7.35 million. The enterprise value is $12.26 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 17.29 million shares outstanding. The number of shares has increased by 955.33% in one year.
| Current Share Class | 17.29M |
| Shares Outstanding | 17.29M |
| Shares Change (YoY) | +955.33% |
| Shares Change (QoQ) | -65.55% |
| Owned by Insiders (%) | 7.76% |
| Owned by Institutions (%) | 13.10% |
| Float | 12.15M |
Valuation Ratios
The trailing PE ratio is 0.51.
| PE Ratio | 0.51 |
| Forward PE | n/a |
| PS Ratio | 5.48 |
| Forward PS | 27.67 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.17 |
| EV / Sales | 12.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52, with a Debt / Equity ratio of 0.30.
| Current Ratio | 0.52 |
| Quick Ratio | 0.42 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,035.58 |
Financial Efficiency
Return on equity (ROE) is 1,066.81% and return on invested capital (ROIC) is -46.67%.
| Return on Equity (ROE) | 1,066.81% |
| Return on Assets (ROA) | -40.40% |
| Return on Invested Capital (ROIC) | -46.67% |
| Return on Capital Employed (ROCE) | -80.65% |
| Revenue Per Employee | $26,154 |
| Profits Per Employee | $1.80M |
| Employee Count | 39 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 2.42 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.42% in the last 52 weeks. The beta is 1.09, so PAVmed's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -64.42% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 39.66 |
| Average Volume (20 Days) | 266,851 |
Short Selling Information
The latest short interest is 175,277, so 1.01% of the outstanding shares have been sold short.
| Short Interest | 175,277 |
| Short Previous Month | 211,296 |
| Short % of Shares Out | 1.01% |
| Short % of Float | 1.44% |
| Short Ratio (days to cover) | 0.75 |
Income Statement
In the last 12 months, PAVmed had revenue of $1.02 million and earned $70.05 million in profits. Earnings per share was $0.83.
| Revenue | 1.02M |
| Gross Profit | -487,000 |
| Operating Income | -26.93M |
| Pretax Income | -61.46M |
| Net Income | 70.05M |
| EBITDA | -26.55M |
| EBIT | -26.93M |
| Earnings Per Share (EPS) | $0.83 |
Full Income StatementBalance Sheet
The company has $4.38 million in cash and $9.31 million in debt, giving a net cash position of -$4.93 million or -$0.29 per share.
| Cash & Cash Equivalents | 4.38M |
| Total Debt | 9.31M |
| Net Cash | -4.93M |
| Net Cash Per Share | -$0.29 |
| Equity (Book Value) | 31.42M |
| Book Value Per Share | 0.64 |
| Working Capital | -5.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.55 million and capital expenditures -$24,000, giving a free cash flow of -$11.57 million.
| Operating Cash Flow | -11.55M |
| Capital Expenditures | -24,000 |
| Free Cash Flow | -11.57M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
Gross margin is -47.75%, with operating and profit margins of -2,639.71% and 7,144.80%.
| Gross Margin | -47.75% |
| Operating Margin | -2,639.71% |
| Pretax Margin | 6,681.67% |
| Profit Margin | 7,144.80% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -955.33% |
| Shareholder Yield | -955.33% |
| Earnings Yield | 956.49% |
| FCF Yield | -158.01% |
Dividend DetailsAnalyst Forecast
The average price target for PAVmed is $19.00, which is 4,370.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 4,370.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on December 7, 2023. It was a reverse split with a ratio of 1:15.
| Last Split Date | Dec 7, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
PAVmed has an Altman Z-Score of -9.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.65 |
| Piotroski F-Score | 2 |
